Please login to the form below

Not currently logged in
Email:
Password:

India denies Vertex patent on cystic fibrosis drug Orkambi

Says treatment is neither innovative or more effective than its predecessor

Vertex PharmaceuticalsThe Indian Patent Office has refused a patent to Vertex Pharma for its cystic fibrosis therapy Orkambi, saying the drug is not novel.

The rejection of the International Patent Application (No. PCT/US2008/085456) covers solid forms of lumacaftor one of the active ingredients in Orkambi which to date has been launched onto the market only in the US and Germany.

The ruling could mean that generic versions of Orkambi become available in India even as Vertex is still rolling out its product in other world markets.

Orkambi combines another Vertex CF treatment - Kalydeco (ivacaftor) - with lumacaftor in order to tackle two different genetic mutations in the disease.

Analysts have suggested it could eventually become a $5bn-a-year product, thanks to a list price of almost $260,000 a year. In 2015 Kalydeco and Orkambi brought in $632m and $351m, respectively.

India's Kolkata Patent Office declined to approve the Indian version of this patent - first filed in 2008 - on the grounds that most of the claims are obvious and do not involve an inventive step. It also maintains that lumacaftor is a new form of a known substance.

According to consultancy TwoFour Insight, the patent office concluded that "the claimed polymorphic forms and process of preparation in the absence of better efficacy results are considered as mere new form and process respectively and thus, not patentable under section 3(d)”.

The patent office also concluded that better bioavailability does not necessarily lead to better efficacy, according to TwoFour.

Under India's intellectual property law, Section 3(d) does not allow a new form of a drug such as a new crystal structure to be patented unless it confers a therapeutic advantage over the original substance.

The patent was opposed by the Indian Pharmaceutical Alliance (IPA), a trade organisation representing India's larger pharmaceutical companies, including Cipla, Dr Reddy's Labs, Lupin, Nicholas Piramal, Ranbaxy and Wockhardt.

CF is around four times less common in Indian people than Caucasians but - due to the size of the Indian population - it has been estimated that there are actually more patients with the disease than in Europe.

Article by
Phil Taylor

1st April 2016

From: Regulatory

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Onyx Health Ltd

Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...

Latest intelligence

Want to give perfect client service? Tough luck, you’re human
In this article an ex-client of mine, Liz Skrbkova, and I explore the (unhelpful) pressures of trying to perfect the client-agency relationship...
WHITE PAPER: Why do men die younger?
It’s a commonly accepted fact that women outlive men. Wherever you live, there’s a good chance that men will die on average eight years earlier than women. Is this an...
3 tips to show patient diversity in your clinical trial materials
Here are some useful tips to help get your hands on authentically diverse stock photos....

Infographics